- Home
- SWIN vs INKT Comparison
SWIN vs INKT Comparison
Compare SWIN & INKT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SWIN
- INKT
- Stock Information
- Founded
- SWIN 2017
- INKT 2017
- Country
- SWIN Hong Kong
- INKT United States
- Employees
- SWIN N/A
- INKT N/A
- Industry
- SWIN
- INKT Medicinal Chemicals and Botanical Products
- Sector
- SWIN
- INKT Health Care
- Exchange
- SWIN Nasdaq
- INKT Nasdaq
- Market Cap
- SWIN 32.1M
- INKT 28.8M
- IPO Year
- SWIN 2023
- INKT 2021
- Fundamental
- Price
- SWIN $3.29
- INKT $62.86
- Analyst Decision
- SWIN
- INKT Strong Buy
- Analyst Count
- SWIN 0
- INKT 2
- Target Price
- SWIN N/A
- INKT $37.50
- AVG Volume (30 Days)
- SWIN 272.7K
- INKT 2.4M
- Earning Date
- SWIN 08-21-2025
- INKT 08-12-2025
- Dividend Yield
- SWIN N/A
- INKT N/A
- EPS Growth
- SWIN N/A
- INKT N/A
- EPS
- SWIN N/A
- INKT N/A
- Revenue
- SWIN $3,316,000.00
- INKT N/A
- Revenue This Year
- SWIN $29.79
- INKT N/A
- Revenue Next Year
- SWIN $54.60
- INKT N/A
- P/E Ratio
- SWIN N/A
- INKT N/A
- Revenue Growth
- SWIN N/A
- INKT N/A
- 52 Week Low
- SWIN $1.16
- INKT $4.56
- 52 Week High
- SWIN $4.40
- INKT $76.00
- Technical
- Relative Strength Index (RSI)
- SWIN 58.50
- INKT 57.39
- Support Level
- SWIN $2.88
- INKT $6.80
- Resistance Level
- SWIN $4.40
- INKT $7.88
- Average True Range (ATR)
- SWIN 0.48
- INKT 0.40
- MACD
- SWIN 0.01
- INKT 0.02
- Stochastic Oscillator
- SWIN 47.14
- INKT 58.86
About SWIN Solowin Holdings
Solowin Holdings Ltd is a investor-focused, versatile securities brokerage company in Hong Kong. It offers a wide spectrum of products and services through its secured one-stop electronic platform. It is engaged in providing securities related services, investment advisory service, and asset management service to customers. The operations were organized into four reportable segments: securities related services, investment advisory services, corporate consultancy services, and asset management services. It derives maximum revenue from investment advisory services.
About INKT MiNK Therapeutics Inc.
MiNK Therapeutics Inc is a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. The company is advancing a pipeline of both native and next generation engineered iNKT programs, with a platform designed to facilitate scalable and reproducible manufacturing for off-the-shelf delivery.